Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 4 1Phase 2 1

Status

Completed 11Terminated 3Unknown 2Recruiting 2Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Acetaminophen Exposure 1

Interventions

Metformin 3Letrozole 3Sperm Injections, Intracytoplasmic 2Progesterone 2Lidocaine 2Indocyanine Green 2Gentamicins 2Estradiol 2Clomiphene 2Bevacizumab 2Acitretin 2tirbanibulin 1technetium Tc 99m nanocolloid 1suvorexant 1pomalidomide 1pembrolizumab 1pasireotide 1nilotinib 1methylnaltrexone 1ledipasvir 1ixazomib 1gadolinium ethoxybenzyl DTPA 1gadofosveset trisodium 1exemestane 1encorafenib 1dolutegravir 1ceftolozane, tazobactam drug combination 1binimetinib 1bicalutamide 1apatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Withdrawn × Acetaminophen × Clear all
NCT02911961 2021-09-02

APAP-CYS Protein Adduct Concentrations in Patients With Liver-Directed Therapy Intended to Treat Hepatic Tumors

Denver Health and Hospital Authority

Phase 4 Withdrawn

Acetaminophen Exposure

Data powered by HemOnc (CC BY 4.0) Colophon âš¡